Single case reports have shown enhanced activity of the pathway by increased basal Akt and S6 phosphorylation levels, downstream of the PI3K, in the primary T and B lymphocytes of patients with APDS. This evidence concerns the gene AKT1 and activated PI3K-delta syndrome.